We act as international experts for the formulation of scoping questions, the conduction of systematic reviews and GRADE of the evidence for the WHO GDG. We officially and actively participate to the annual mhGAP forum.

 http://www.who.int/mental_health/mhgap/evidence/en/

We are part of the experts team that collaborates with the WHO to design the structure, revise the content and envisage the piloting, evaluation and implementation steps of the mhGAP intervention guide.

http://www.who.int/mental_health/mhgap/evidence/dementia/fr/

Prof. Albanese has contributed as main author to a number of World Alzheimer Reports in the past years; from the global epidemiology of dementia, to its risk and protective factors and nutritional aspects in clinical management. 

https://www.alz.co.uk/research/world-report

Our WHO CC has been one of the key academic contributor to this WHO historic event, which paved the way towards the development of a “Global Dementia Action Plan” led by the WHO.

http://www.who.int/mediacentre/events/meetings/2015/global-action-against-dementia/en/

Prof. Albanese is part of both the WHO Advisory and Expert groups that have conducted, during 2015 a CHNRI global exercise to establish the research priorities in the field of dementia. The goal of this unprecedented exercise is to assist policy makers, funders and Member States to develop a sound, informed and coordinated research agenda to advance dementia research globally, and reduce the burden of the disease worldwide.

Preliminary results of the Prioritization exercises were presented at the WHO Ministerial Conference in 2015.

As of June 2016, we are finalizing a WHO report and a peer-reviewed publication to maximize the dissemination of the results.

A complex and structured mapping of all funded dementia research worldwide has been conducted. The results of this ambitious survey are now being combined with those of the research prioritization exercise (above) to inform the research agenda optimizing investments.

The purpose of the Global Dementia Observatory (GDO) is to provide evidence-based service planning and strengthening of policies in health and social care systems with comparable indicators. It will include data on burden and impact; policy; services and resources; as well as research and innovation. The Global Dementia Observatory will also function as a knowledge translation and exchange platform.

Our WHO CC is actively involved in the development, piloting and scaling up of the GDO, also in collaboration with the Swiss Office Fédéral de Santé Publique (OFSP/ BAG).

iSupport is an online platform for caregivers and family members of people with dementia. It includes educational and training contents, and a unique algorithm used to tailor the use of the platform dynamically and to best respond to the actual needs of the carers through the progression of dementia.

http://www.who.int/mental_health/neurology/dementia/isupport/en/

Our WHO CC has designed and developed the aforementioned algorithm with support from the Association pour la Recherche sur Alzheimer (anciennement Association IFRAD Suisse; https://recherchealzheimer.ch/)

Prof Albanese is part of the Steering Group who gave advice and contributed to the development of the WHO iCOPE guidelines aimed at providing a new evidence-based approach for health care providers for prevention of declines in intrinsic capacity (physical and mental) and care dependence in older age.

http://www.who.int/ageing/health-systems/integrated-care/en/

Prof Albanese wrote the chapter on epidemiology and impact of dementia.

http://dcp-3.org/mentalhealth

The WHO CC promotes all research and clinical efforts directed towards a substantial improvement of timely diagnosis of dementia. Prof. Albanese collaborates with Prof. Frisoni and Dr. Idris Guessous (HUG: http://www.hug-ge.ch/medecine-premier-recours/unite-epidemiologie-populationnelle-1) to integrate dementia and cognitive impairment into the Bus Santé annual population-based surveys  conducted in Geneva.

LANVIE laboratory: https://www.unige.ch/medecine/psyat/en/research-groups/935frisoni/

PhD Program in Global Health – Dr. Melissa Harper and Dr. Mark van Ommeren, WHO

https://www.euro.who.int/en/media-centre/events/events/2021/11/who-collaborating-centres-regional-meeting-united-action-for-better-health-in-europe 

Brief overview of the WHO Collaborative Project on the Development of New International Screening and Diagnostic Instruments for Gaming Disorder and Gambling Disorder

Article publié dans la Revue ADDICTION et résumant le projet

ARTICLES 

• Reed GM, First MB, Billieux J, Cloitre M, Briken P, Achab S, Brewin CR, King DL, et al. Emerging experience with selected new categories in the ICD‐11: complex PTSD, prolonged grief disorder, gaming disorder, and compulsive sexual behaviour disorder. World Psychiatry 2022;21(2):189-213.
• Castro‐Calvo J, King DL, Stein DJ, Brand M, Carmi L, Chamberlain SR, Demetrovics Z, Fineberg NA, et al. Expert appraisal of criteria for assessing gaming disorder: An international Delphi study. Addiction Biology 2021.
• King DL, Chamberlain SR, Carragher N, Billieux J, Stein D, Mueller K, Potenza MN, Rumpf HJ, et al. Screening and assessment tools for gaming disorder: A comprehensive systematic review. Clinical Psychology Review 2020;77:101831.
• King DL. Comment on the global gaming industry's statement on ICD-11 gaming disorder: a corporate strategy to disregard harm and deflect social responsibility? Addiction 2018;113(11):2145-2146.
• Rumpf H-J, Achab S, Billieux J, Bowden-Jones H, Carragher N, Demetrovics Z, Higuchi S, King DL, et al. Including gaming disorder in the ICD-11: The need to do so from a clinical and public health perspective. Journal of Behavioral Addictions 2018;7(3):556-561.
• Billieux J, King D, Higuchi S, Achab S, Bowden-Jones H, Hao W, Long J, Lee HK, et al. Functional impairment matters in the screening and diagnosis of gaming disorder. Journal of Behavioral Addictions 2017;6(3):285-289.
• Saunders JB, Hao W, Long J, King DL, Mann K, Fauth-Bühler M, Rumpf H-J, Bowden-Jones H, et al. Gaming disorder: Its delineation as an important condition for diagnosis, management, and prevention. Journal of Behavioral Addictions 2017:1-9.

National Case Studies

Needs for treatment at a Global level

Capacity building of care professionals at a Global level

Covid-19 pandemic impact

 

 

http://www.who.int/substance_abuse/publications/management_opioid_overdose/en/ 

http://who.int/goe/data/en/ 

http://www.who.int/mental_health/mhgap/evidence/mhgap_guideline_update_2015.pdf 

https://www.unodc.org/ddt-training/treatment/a.html 

http://www.who.int/substance_abuse/activities/assist/en/